Fund moves
49.9%Stake
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PTHS · NYSE · Biological Products, (No Diagnostic Substances)
Pelthos Therapeutics (PTHS) · oqro.io/stocks/PTHS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Pelthos Therapeutics was filed in the last 90 days. The latest on record was on Sep 13, 2024.
Since 2024, Pelthos Therapeutics insiders reported 6 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2024.
No open-market sale by an insider of Pelthos Therapeutics (PTHS) was filed with the SEC in the last 90 days.
No trade in Pelthos Therapeutics (PTHS) was disclosed by a member of Congress in the last 12 months.
Pelthos Therapeutics's next results are expected on Mar 17, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$6.38−0.61 (−8.73%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−78.0% (−$22.62) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $29.00 on Nov 20, 2025 to $6.38 on Nov 20, 2026 (−78.0%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Durham, Nc.
Last 12 months
−78.0%
Market value
$26.9M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 158K shares sold short (3.8% of shares outstanding), +11.4% vs the previous count, 2.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$16.8M
Year ended Dec 31, 2025
Net income, fiscal 2025
−$43.3M
A loss for the year
Shares outstanding
3.93M
As of Nov 5, 2026
Fund moves
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Past financial statements can no longer be relied on
8-K on sec.govAdmitted a material weakness in internal controls
10-Q/A on sec.govChanged auditor
8-K on sec.govTop officer leaving
“As previously disclosed, the Board terminated Francis Knuettel II from his position as Chief Financial Officer, Treasurer and Secretary of the Company, effective April 10, 2026.”
8-K on sec.govTop officer leaving
“Gay as Chief Financial Officer, the Board terminated Francis Knuettel II from his position as Chief Financial Officer of the Company, effective April 10, 2026.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Insiders of Pelthos Therapeutics reported 6 open-market purchases and 0 sales since 2024; purchases in 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $126K6×6 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Revenue
$15.4M
+107.9% vs the same quarter a year earlier
Free cash flow, last 12 months
−$32.6M
This quarter −$5.22M, a year earlier −$15.3M
Net debt
—
Debt —, cash $17.7M, at Sep 30, 2026
Net income, last 12 months
−$78M
Operating loss: profit did not cover interest (latest fiscal year)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Revenue and earnings history, 4 fiscal yearsEarnings dates and the stock's moves
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Deals
Things to keep in mind
Last results
Nov 12, 2026
Within the 30 days after it, until Dec 12, 2026
Next results, expected
Mar 17, 2027
Purchases after results
Not enough history
From Pelthos Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Pelthos Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Ligand Pharmaceuticals Incorporated
13D · may seek influence · Amended · 5.19M shares · filed Nov 3, 2026
3i, LP
13G · passive · Amended · 383K shares · filed Nov 12, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Off-exchange trading: 18.9% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (6.9% on ATS, 12.0% with other brokers), below its 26-week average of 36.3%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (24.2%), INSTINCT X (17.6%), SIGMA X2 (13.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Latest annual report filed Mar 19, 2026. Read the filing
The risk factors section was largely rewritten: most of its 60 headings have no close match among the 71 of the year before, so no list of changes is shown.
From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of our management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputation harm, and other factors.
Source: SEC EDGAR, Form 10-K filed Mar 19, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Mar 19, 2026. Read the filing
$0 the year before
$0 the year before
$0 the year before
$0 the year before
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 16,000 words.
Pelthos Therapeutics Inc. is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three FDA approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI®, and XEGLYZE®. The Merger between Channel and LNHC resulted in the Company initially having (i) a commercially marketable product, ZELSUVMI for the treatment of molluscum contagiosum, which was launched in July 2025 shortly after the Merger; (ii) a manufacturing facility, equipment and know-how to produce the API used in ZELSUVMI and the NITRICILTM technology platform; and (iii) clinical-stage assets which selectively target the sodium ion-channel known…
Source: SEC EDGAR, Form 10-K filed Mar 19, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
And 26 more headings in the filing.